Obeticholic Acid is a novel derivative of chenodeoxycholic acid (CDCA) in human primary bile acids and is  tested for the treatment of primary biliary cirrhosis and nonalcoholic fatty liver disease, Common fatty liver - nonalcoholic fatty liver disease. During six weeks clinical trial in multicenter, randomized, double-blind from the United States of America included 64 patients with type 2 diabetes mellitus combined with nonalcoholic fatty liver disease (NAFLD), demonstrating that Obeticholic Acid increases insulin sensitivity , But can improve liver inflammation and fibrosis, and have a certain role in reducing body weight resistance Division. But this conclusion still needs a long-term follow-up, and also need for liver pathology to confirm.

Thera. Category:  Cholestatic liver disease

Cas No.: 459789-99-2

Synonym:  6-Ethylchenodeoxycholic acid;C15636;Ocaliva;6-Ecdca;DSP-1747;6-Ethyl-cdca;Obeticholic Acid;Obetichlolic Acid;6alpha-Ethyl-chenodeoxycholic acid;6-Ethylchenodeoxycholic acid(Obeticholic Acid)

Molecular Formula:C26H44O4

Molecular Weight: 420.63

Purity: ≥98.%

Packing:Export worthy packing

Material Safety Data Sheet:Available on request

Obeticholic acid (Obeticholic Acid), also known as 6-ethyl chenodeoxycholic acid, is a new derivative of chenodeoxycholic acid (CDCA) in the primary bile acid, and a natural ligand for the farneside derivatives X receptor ( FXR). Oberbetaine is an agonist for farnesol X receptor, inhibiting gene expression of cytochrome 7A1 (CYP7A1) by activating the farnesol X receptor. Because CYP7A1 is the rate-limiting enzyme for biosynthesis of cholic acid, it can inhibit cholic acid synthesis and is useful in the treatment of primary biliary cirrhosis and nonalcoholic fatty liver disease.

Related products:

Obeticholic Acid Cas 459789-99-2 

6 - ethyl - 3 - hydroxy - 7 - oxo -, (3α, 5β, 6β) - CAS 915038-24-3

3α-hydroxy-6-ethyl-7-keto-5β-cholan-24-oic acid  CAS 915038-26-5

Obeticholic Acid  Intermediate 3 CAS number is 1516887-33-4